Synthetic Vaccines against Cancers

Fiore, Michele; Thomas, Baptiste; Daskhan, Gour Chand; Renaudet, Olivier

doi:10.1142/9781783267200_0014

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] OMVs have some disadvantages: they are not easy to produce and isolate from GN bacterial cultures with consequent issues in their characterization. [1,18] In addition, the presence of toxic lipo-polysaccharides (LPS) prevents the medical use of OMVs directly obtained from natural sources. [19] To solve these drawbacks we hypothesized that synthetic OMVs (S-OMVs), composed of mixtures of "onpurpose" prepared glycolipids and non-toxic and non-immunogenic phospholipids in variable compositions could be good candidates for different uses such as synthetic vaccines or vaccine carriers (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Synthetic Outer Membrane Vesicles Bearing Tn Antigen

Chieffo,

Comte,

Strazewski

et al. 2023

Eur J Org Chem

View full text Add to dashboard Cite

: N‐alkyl‐thio glycolipids (TGL) are proposed as fundamental components in the production of synthetic outer membrane vesicles (S‐OMVs). A small but representative library of glycolipids was prepared by thiol‐ene coupling (TEC), using unprotected thiols in acceptable to good yields (63‐96%). Multilamellar giant vesicles (GVs) of varying sizes were assembled from mixtures of TGL and 1‐palmitoyl‐2‐oleoyl‐sn‐glycero‐3‐phosphate (POPC). Our results mark an important advancement for the development of synthetic anticancer vaccines, supramolecular adjuvants and drug delivery systems based on glycolipid/phospholipid formulations (10 % mol/mol in 0.1 mm solution).

show abstract

Section: Introductionmentioning

confidence: 99%

Synthetic Outer Membrane Vesicles Bearing Tn Antigen

Chieffo,

Comte,

Strazewski

et al. 2023

Eur J Org Chem

View full text Add to dashboard Cite

show abstract

Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines

Pifferi

Thomas

Goyard

et al. 2017

Chemistry A European J

Self Cite

View full text Add to dashboard Cite

The large majority of TACA‐based (TACA=Tumor‐Associated Carbohydrate Antigens) antitumor vaccines target only one carbohydrate antigen, thereby often resulting in the incomplete destruction of cancer cells. However, the morphological heterogeneity of the tumor glycocalix, which is in constant evolution during malignant transformation, is a crucial point to consider in the design of vaccine candidates. In this paper, an efficient synthetic strategy based on orthogonal chemoselective ligations to prepare fully synthetic glycosylated cyclopeptide scaffolds grafted with both Tn and TF antigen analogues is reported. To evaluate their ability to be recognized as tumor antigens, direct interaction ELISA assays have been performed with the anti‐Tn monoclonal antibody 9A7. Although both heterovalent structures showed binding capacities with 9A7, the presence of the second TF epitope did not interfere with the recognition of Tn except in one epitope arrangement. This heterovalent glycosylated structure thus represents an attractive epitope carrier to be further functionalized with T‐cell peptide epitopes.

show abstract

Synthetic Vaccines against Cancers

Cited by 2 publications

References 48 publications

Synthetic Outer Membrane Vesicles Bearing Tn Antigen

Synthetic Outer Membrane Vesicles Bearing Tn Antigen

Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines

Contact Info

Product

Resources

About